event,time
61 years old ,0.0
    female ,0.0
    severe community-acquired pneumonia ,0.0
    acute renal failure ,0.0
    type 2 diabetes mellitus ,0.0
    chronic obstructive airway disease ,0.0
    acute tubular necrosis ,0.0
    sepsis ,0.0
    hypotension ,0.0
    urine without red cells or casts ,0.0
    initial stable renal function ,0.0
    rapid worsening renal function ,24.0
    significant fluid overload ,24.0
    4 sessions of haemodialysis ,24.0
    improved renal function ,24.0
    became dialysis independent ,24.0
    discharged home after 45 days ,1080.0
    acute pulmonary oedema ,1080.0
    skin rash ,1080.0
    readmission to ICU within 48h of discharge ,1128.0
    pulmonary hypertension ,1128.0
    splenomegaly ,1128.0
    hepatomegaly ,1128.0
    bilateral pleural effusion ,1128.0
    skin lesions typical of vasculitis ,1128.0
    dysmorphic red cells in urine ,1128.0
    proteinuria ,1128.0
    hypoalbuminaemia ,1128.0
    low complement levels ,1128.0
    positive serology for mixed cryoglobulinaemia ,1128.0
    normal renal ultrasound ,1128.0
    weakly positive rheumatoid factor ,1128.0
    negative HCV RNA ,1128.0
    negative autoimmune screens ,1128.0
    renal biopsy findings ,1128.0
    5 sessions of plasma exchange ,1128.0
    2 sessions of haemodialysis ,1128.0
    prednisolone ,1128.0
    cyclophosphamide ,1128.0
    decrease in cryoglobulin levels within 3 weeks ,168.0
    symptomatic improvement ,168.0
    discontinued cyclophosphamide due to thrombocytopenia ,168.0
    discharged on prednisolone 50 mg ,168.0
    normal renal function on discharge ,168.0
    symptomatic again after 2 weeks ,384.0
    reappearance of rash ,384.0
    positive/high serum cryoglobulins ,384.0
    low complements ,384.0
    worsening proteinuria ,384.0
    significant weight gain ,384.0
    high urea level ,384.0
    5 sessions of plasmapheresis ,384.0
    recommenced cyclophosphamide 50 mg/100 alternate days ,384.0
    discharged again with normal renal function ,384.0
    negative serum cryoglobulin ,384.0
    represented with fluid overload and pneumonia after 12 days ,624.0
    cyclophosphamide ceased due to thrombocytopenia ,624.0
    sepsis ,624.0
    herpes zoster ,624.0
    intermittent haemodialysis ,624.0
    plasmapheresis on alternate days for 1 month ,624.0
    new-onset paraproteinaemia ,624.0
    monoclonal IgM kappa ,624.0
    negative Bence Jones protein ,624.0
    normal skeletal survey ,624.0
    no light chains in serum ,624.0
    bone marrow biopsy showing low-grade lymphoma ,624.0
    CD20 expression on B cells ,624.0
    no clinical improvement ,624.0
    regular dialysis/ultrafiltration ,624.0
    given 600 mg rituximab/week for 3 weeks ,624.0
    responded within 1 week ,744.0
    dramatic improvement in symptoms ,744.0
    absence of cryoglobulins ,744.0
    normal complement levels ,744.0
    prior infections ,744.0
    discharged on prednisolone and haemodialysis ,744.0
    renal function gradually improved ,744.0
    became dialysis independent after 7 months ,5040.0
    complete renal recovery ,5040.0
    cryoglobulin titres negative ,5040.0
    normal serum complements ,5040.0
    continues on prednisolone 5 mg daily ,5040.0
    no side effects ,5040.0
    no infections on follow-up ,5040.0
    acute renal failure attributed to sepsis and hypotension ,0.0
    fluid overload requiring haemodialysis ,24.0
    pulmonary oedema and rash readmission ,1080.0
    vasculitic skin lesions ,1128.0
    mesangiocapillary glomerulonephritis ,1128.0
    hyaline capillary thrombi ,1128.0
    focal mild endarteritis ,1128.0
    plasmapheresis and haemodialysis ,1128.0
    thrombocytopenia leading to cyclophosphamide discontinuation ,168.0
    recurrent thrombocytopenia ,624.0
    herpes zoster chest wall ,624.0
    low-grade lymphoma with CD20 B cells ,624.0
    rituximab addition to prednisolone ,624.0
    three doses of rituximab ,624.0
    pancytopenia secondary to cytotoxics ,624.0
    sepsis predating rituximab ,624.0
    prednisolone maintenance ,5040.0
    no clinical recurrence ,5040.0
    no serological recurrence ,5040.0
    complete renal recovery ,5040.0
    negative cryoglobulins ,5040.0
    normal complements ,5040.0
    no maintenance therapy required ,5040.0
    no long-term oncogenetic effects ,5040.0
    61 years old ,0.0
    female ,0.0
    severe community-acquired pneumonia ,0.0
    acute renal failure ,0.0
    type 2 diabetes mellitus ,0.0
    chronic obstructive airway disease ,0.0
    acute tubular necrosis ,0.0
    sepsis ,0.0
    hypotension ,0.0
    urine without red cells or casts ,0.0
    initial stable renal function ,0.0
    rapid worsening renal function ,24.0
    significant fluid overload ,24.0
    4 sessions of haemodialysis ,24.0
    improved renal function ,24.0
    became dialysis independent ,24.0
    discharged home after 45 days ,1080.0
    acute pulmonary oedema ,1080.0
    skin rash ,1080.0
    readmission to ICU within 48h of discharge ,1128.0
    pulmonary hypertension ,1128.0
    splenomegaly ,1128.0
    hepatomegaly ,1128.0
    bilateral pleural effusion ,1128.0
    skin lesions typical of vasculitis ,1128.0
    dysmorphic red cells in urine ,1128.0
    proteinuria ,1128.0
    hypoalbuminaemia ,1128.0
    low complement levels ,1128.0
    positive serology for mixed cryoglobulinaemia ,1128.0
    normal renal ultrasound ,1128.0
    weakly positive rheumatoid factor ,1128.0
    negative HCV RNA ,1128.0
    negative autoimmune screens ,1128.0
    renal biopsy findings ,1128.0
    5 sessions of plasma exchange ,1128.0
    2 sessions of haemodialysis ,1128.0
    prednisolone ,1128.0
    cyclophosphamide ,1128.0
    decrease in cryoglobulin levels within 3 weeks ,168.0
    symptomatic improvement ,168.0
    discontinued cyclophosphamide due to thrombocytopenia ,168.0
    discharged on prednisolone 50 mg ,168.0
    normal renal function on discharge ,168.0
    symptomatic again after 2 weeks ,384.0
    reappearance of rash ,384.0
    positive/high serum cryoglobulins ,384.0
    low complements ,384.0
    worsening proteinuria ,384.0
    significant weight gain ,384.0
    high urea level ,384.0
    5 sessions of plasmapheresis ,384.0
    recommenced cyclophosphamide 50 mg/100 alternate days ,384.0
    discharged again with normal renal function ,384.0
    negative serum cryoglobulin ,384.0
    represented with fluid overload and pneumonia after 12 days ,624.0
    cyclophosphamide ceased due to thrombocytopenia ,624.0
    sepsis ,624.0
    herpes zoster ,624.0
    intermittent haemodialysis ,624.0
    plasmapheresis on alternate days for 1 month ,624.0
    new-onset paraproteinaemia ,624.0
    monoclonal IgM kappa ,624.0
    negative Bence Jones protein ,624.0
    normal skeletal survey ,624.0
    no light chains in serum ,624.0
    bone marrow biopsy showing low-grade lymphoma ,624.0
    CD20 expression on B cells ,624.0
    no clinical improvement ,624.0
    regular dialysis/ultrafiltration ,624.0
    given 600 mg rituximab/week for 3 weeks ,624.0
    responded within 1 week ,744.0
    dramatic improvement in symptoms ,744.0
    absence of cryoglobulins ,744.0
    normal complement levels ,744.0
    prior infections ,744.0
    discharged on prednisolone and haemodialysis ,744.0
    renal function gradually improved ,744.0
    became dialysis independent after 7 months ,5040.0
    complete renal recovery ,5040.0
    cryoglobulin titres negative ,5040.0
    normal serum complements ,5040.0
    continues on prednisolone 5 mg daily ,5040.0
    no side effects ,5040.0
    no infections on follow-up ,5040.0
    acute renal failure attributed to sepsis and hypotension ,0.0
    fluid overload requiring haemodialysis ,24.0
    pulmonary oedema and rash readmission ,1080.0
    vasculitic skin lesions ,1128.0
    mesangiocapillary glomerulonephritis ,1128.0
    hyaline capillary thrombi ,1128.0
    focal mild endarteritis ,1128.0
    plasmapheresis and haemodialysis ,1128.0
    thrombocytopenia leading to cyclophosphamide discontinuation ,168.0
    recurrent thrombocytopenia ,624.0
    herpes zoster chest wall ,624.0
    low-grade lymphoma with CD20 B cells ,624.0
    rituximab addition to prednisolone ,624.0
    three doses of rituximab ,624.0
    pancytopenia secondary to cytotoxics ,624.0
    sepsis predating rituximab ,624.0
    prednisolone maintenance ,5040.0
    no clinical recurrence ,5040.0
    no serological recurrence ,5040.0
    complete renal recovery ,5040.0
    negative cryoglobulins ,5040.0
    normal complements ,5040.0
    no maintenance therapy required ,5040.0
    no long-term oncogenetic effects ,5040.0
"Alright, I need to extract all the clinical events from this case report and assign timestamps to each. The admission event is at 0 hours, and all other events should be assigned relative times based on when they occurred before or after admission. If the exact time isn't given, I need to estimate it using context. ",
"First, the patient is a 61-year-old female with several background conditions: type 2 diabetes mellitus and chronic obstructive airway disease. These are present at admission, so their timestamps are 0. She presents with severe community-acquired pneumonia and acute renal failure, both at admission time (0). The renal failure is due to acute tubular necrosis from sepsis and hypotension, which are also at 0. The initial urine analysis shows no red cells or casts, so that's at 0 too.",
"Her renal function initially stays stable but then worsens rapidly. Since this happens after admission, I need to figure out the timing. The report mentions she required 4 sessions of hemodialysis in the ICU. The timeline says her renal function worsened ""initially remained stable and then worsened rapidly,"" which I assume happened within the first day. So, I'll assign 24 hours for the rapid worsening, significant fluid overload, and the 4 hemodialysis sessions. Her renal function improves and she becomes dialysis independent, which also happens at 24 hours. She's discharged after 45 days, which converts to 1080 hours (45 * 24).",
"She then returns with acute pulmonary edema and skin rash within 48 hours of discharge. Since discharge was at 1080 hours, readmission is at 1080 + 48 = 1128 hours. At readmission, physical exam findings like pulmonary hypertension, splenomegaly, hepatomegaly, bilateral pleural effusion, and vasculitic skin lesions are noted. These are at 1128. Lab results (dysmorphic red cells, proteinuria, hypoalbuminemia, low complements, positive cryoglobulinaemia serology) are also at 1128. Imaging and biopsy results (normal kidneys, weakly positive RF, negative HCV, autoimmune screens, renal biopsy findings) are part of the readmission, so 1128.",
"She receives 5 plasma exchanges and 2 hemodialysis sessions over a week, starting at readmission (1128). Prednisolone and cyclophosphamide are started here. Within 3 weeks (168 hours after 1128), cryoglobulin levels decrease and symptoms improve. But cyclophosphamide is discontinued due to thrombocytopenia at 168. She's discharged on prednisolone 50 mg with normal renal function at 168.",
"After 2 weeks (384 hours from discharge), she becomes symptomatic again with rash, high cryoglobulins, low complements, worsening proteinuria, weight gain, and high urea. She gets 5 plasmapheresis sessions, restarts cyclophosphamide, and is discharged again at 384.",
"12 days later (12 * 24 = 288, so 384 + 288 = 672?), she presents with fluid overload and pneumonia. Wait, the report says ""after 12 days"" from the previous discharge. If the previous discharge was at 384, 12 days later is 384 + 288 = 672 hours. Cyclophosphamide is stopped due to thrombocytopenia, sepsis, herpes zoster. She starts intermittent hemodialysis and plasmapheresis. New paraproteinemia, monoclonal IgM, negative Bence Jones, normal survey, no light chains, bone marrow biopsy showing lymphoma with CD20 B cells. These are at 672. No improvement, so rituximab is started at 672. She receives 3 weekly doses (672, 744, 816). She responds within 1 week (672 + 168 = 840?), but the report says ""responded within 1 week"" after starting rituximab, so 672 + 168 = 840? However, the discharge after rituximab is mentioned next. ",
"Wait, the case report says she was given rituximab for 3 weeks and responded within 1 week. So the response at 744 hours (672 + 72 = 744). She's discharged on prednisolone and hemodialysis. Her renal function improves over 7 months (7 * 30 * 24 = 5040), becoming dialysis independent. Follow-up shows negative cryoglobulins, normal complements, no side effects.",
"Also, other events like herpes zoster, pancytopenia, sepsis predating rituximab, etc., are at 672. The three rituximab doses would be at 672, 744, 816, but the report mentions 3 doses over 3 weeks, so each week apart. However, the exact timing isn't specified, so perhaps it's sufficient to note the start time as 672 and the response at 744.",
"I need to ensure all events are captured and timestamped correctly, separating conjunctive phrases into individual events. For example, ""acute pulmonary oedema and skin rash"" becomes two separate events with the same timestamp. Also, include all pertinent negatives and discontinuations.",
"This process involves parsing the case report step by step, noting each event and its timing based on explicit mentions or inferred timelines. Some events may have the same timestamp if they occur together. The goal is to list every clinical event with an appropriate hour stamp relative to admission at 0.",
</think>,
61 years old ,0.0
female ,0.0
severe community-acquired pneumonia ,0.0
acute renal failure ,0.0
type 2 diabetes mellitus ,0.0
chronic obstructive airway disease ,0.0
acute tubular necrosis ,0.0
sepsis ,0.0
hypotension ,0.0
urine without red cells or casts ,0.0
initial stable renal function ,0.0
rapid worsening renal function ,24.0
significant fluid overload ,24.0
4 sessions of haemodialysis ,24.0
improved renal function ,24.0
became dialysis independent ,24.0
discharged home after 45 days ,1080.0
acute pulmonary oedema ,1080.0
skin rash ,1080.0
readmission to ICU within 48h of discharge ,1128.0
pulmonary hypertension ,1128.0
splenomegaly ,1128.0
hepatomegaly ,1128.0
bilateral pleural effusion ,1128.0
skin lesions typical of vasculitis ,1128.0
dysmorphic red cells in urine ,1128.0
proteinuria ,1128.0
hypoalbuminaemia ,1128.0
low complement levels ,1128.0
positive serology for mixed cryoglobulinaemia ,1128.0
normal renal ultrasound ,1128.0
weakly positive rheumatoid factor ,1128.0
negative HCV RNA ,1128.0
negative autoimmune screens ,1128.0
renal biopsy findings ,1128.0
5 sessions of plasma exchange ,1128.0
2 sessions of haemodialysis ,1128.0
prednisolone ,1128.0
cyclophosphamide ,1128.0
decrease in cryoglobulin levels within 3 weeks ,168.0
symptomatic improvement ,168.0
discontinued cyclophosphamide due to thrombocytopenia ,168.0
discharged on prednisolone 50 mg ,168.0
normal renal function on discharge ,168.0
symptomatic again after 2 weeks ,384.0
reappearance of rash ,384.0
positive/high serum cryoglobulins ,384.0
low complements ,384.0
worsening proteinuria ,384.0
significant weight gain ,384.0
high urea level ,384.0
5 sessions of plasmapheresis ,384.0
recommenced cyclophosphamide 50 mg/100 alternate days ,384.0
discharged again with normal renal function ,384.0
negative serum cryoglobulin ,384.0
represented with fluid overload and pneumonia after 12 days ,624.0
cyclophosphamide ceased due to thrombocytopenia ,624.0
sepsis ,624.0
herpes zoster ,624.0
intermittent haemodialysis ,624.0
plasmapheresis on alternate days for 1 month ,624.0
new-onset paraproteinaemia ,624.0
monoclonal IgM kappa ,624.0
negative Bence Jones protein ,624.0
normal skeletal survey ,624.0
no light chains in serum ,624.0
bone marrow biopsy showing low-grade lymphoma ,624.0
CD20 expression on B cells ,624.0
no clinical improvement ,624.0
regular dialysis/ultrafiltration ,624.0
given 600 mg rituximab/week for 3 weeks ,624.0
responded within 1 week ,744.0
dramatic improvement in symptoms ,744.0
absence of cryoglobul,
